{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:26:28Z","timestamp":1786767988830,"version":"build-2736575974"},"reference-count":28,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,8,10]]},"DOI":"10.1253\/circrep.cr-26-0077","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:09:54Z","timestamp":1781561394000},"page":"1337-1345","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients With Pulmonary Arterial Hypertension\u3000\u2015 Prospective, Multicenter, Open-Label Study \u2015"],"prefix":"10.1253","volume":"8","author":[{"given":"Ryo","family":"Inuzuka","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute of Science Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kuraoka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Fukuoka Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takatsuki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Toho University Omori Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Mihoya","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hyunsoo","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minaka","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Public Health, Center for Community Medicine, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Osaka Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics\/Developmental Pediatrics, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Metropolitan Children\u2019s Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University"},{"name":"Tokyo Metropolitan Children\u2019s Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozaburo","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute of Science Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ploegstra MJ, Ivy DD, Beghetti M, Bonnet D, Alehan D, Ablonczy L, et al. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: Results from the global TOPP registry. <i>Eur Heart J Qual Care Clin Outcomes<\/i> 2024; 10: 66\u201376.","DOI":"10.1093\/ehjqcco\/qcad020"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hu C, Francisco J, Del Re DP, Sadoshima J. Decoding the impact of the Hippo pathway on different cell types in heart failure. <i>Circ J<\/i> 2025; 89: 6\u201315.","DOI":"10.1253\/circj.CJ-24-0171"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Morell E, Gaies M, Fineman JR, Charpie J, Rao R, Sasaki J, et al. Mortality from pulmonary hypertension in the pediatric cardiac ICU. <i>Am J Respir Crit Care Med<\/i> 2021; 204: 454\u2013461.","DOI":"10.1164\/rccm.202011-4183OC"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ueda J, Tsuji A, Aoki T, Asano R, Kiko T, Hayashi H, et al. Phase 2 study to evaluate the efficacy and safety of inhaled nitric oxide therapy in patients with severe right heart failure associated with pulmonary hypertension: Protocol for the PHiNO study. <i>Circ Rep<\/i> 2025; 7: 308\u2013312.","DOI":"10.1253\/circrep.CR-24-0125"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Suzuki T, Iwahashi N, Abe T, Komura N, Abe M, Konishi M, et al. Clinical usefulness of passive leg lifting during right heart catheterization for diagnosing exercise-induced pulmonary hypertension: A pilot study. <i>Circ J<\/i> 2026; 90: 228\u2013231.","DOI":"10.1253\/circj.CJ-25-0515"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Adachi T, Adachi S, Nakano Y, Nishiyama I, Hirose M, Murohara T. Controlling nutritional status score predicts 1-year outcomes in chronic thromboembolic pulmonary hypertension. <i>Circ Rep<\/i> 2024; 6: 381\u2013388.","DOI":"10.1253\/circrep.CR-24-0023"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ishii T, Uchida K, Hosokawa S, Yamagishi H, Doi S. Pharmacological treatment practices for patients with congenital heart disease and pulmonary hypertension in Japan: Insights from the Japanese Association of Congenital Heart Disease Registry (JACPHR). <i>Am J Cardiol<\/i> 2025; 257: 18\u201325.","DOI":"10.1016\/j.amjcard.2025.07.035"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Humbert M, Sitbon O, Guignabert C, Savale L, Boucly A, Gallant-Dewavrin M, et al. Treatment of pulmonary arterial hypertension: Recent progress and a look to the future. <i>Lancet Respir Med<\/i> 2023; 11: 804\u2013819.","DOI":"10.1016\/S2213-2600(23)00264-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Angeli F, Verdecchia P, Reboldi G. Aprocitentan, A dual endothelin receptor antagonist under development for the treatment of resistant hypertension. <i>Cardiol Ther<\/i> 2021; 10: 397\u2013406.","DOI":"10.1007\/s40119-021-00233-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Respir J<\/i> 2023; 61: 2200879.","DOI":"10.1183\/13993003.00879-2022"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>N Engl J Med<\/i> 2013; 369: 809\u2013818.","DOI":"10.1056\/NEJMoa1213917"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tahara N, Dobashi H, Fukuda K, Funauchi M, Hatano M, Ikeda S, et al. Efficacy and safety of a novel endothelin receptor antagonist, macitentan, in Japanese Patients with pulmonary arterial hypertension. <i>Circ J<\/i> 2016; 80: 1478\u20131483.","DOI":"10.1253\/circj.CJ-15-1305"},{"key":"13","unstructured":"13. Opsumit PMDA Review Report. 2015. https:\/\/www.pmda.go.jp\/drugs\/2015\/P20150601007\/100888000_22700AMX00649_A100_1.pdf (accessed September 29, 2025)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Berger RMF, Dunbar Ivy D, Borissoff JI, Cerovic S, Csonka D, Reme\u0148ov\u00e1 T, et al. Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial. <i>J Pediatr<\/i> 2026; 293: 115057.","DOI":"10.1016\/j.jpeds.2026.115057"},{"key":"15","unstructured":"15. EMA Assessment Report. Opsumit: Assessment report on a group of an extension of marketing authorisation and an extension of indication variation. 25 Jul 2024. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/opsumit-h-c-002697-x-0051-g-epar-assessment-report-variation_en.pdf (accessed November 20, 2025)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ogando AR, Sabat\u00e9-Rot\u00e9s A, Bonora AM, de la Torre AL, Esp\u00edn L\u00f3pez JM, de Lera CL, et al. Macitentan in children with pulmonary arterial hypertension: A multicenter experience. <i>Pediatr Cardiol<\/i> 2026; 47: 1572\u20131580.","DOI":"10.1007\/s00246-025-03937-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Albinni S, Heno J, Pavo I, Kitzmueller E, Marx M, Behnke IM. Macitentan in the young\u2013mid-term outcomes of patients with pulmonary hypertensive vascular disease treated in a pediatric tertiary care center. <i>Pediatr Drugs<\/i> 2023; 25: 467\u2013481.","DOI":"10.1007\/s40272-023-00573-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Germovsek E, Barker CIS, Sharland M, Standing JF. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. <i>Clin Pharmacokinet<\/i> 2019; 58: 39\u201352.","DOI":"10.1007\/s40262-018-0659-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bruderer S, Marjason J, Sidharta PN, Dingemanse J. Pharmacokinetics of macitentan in Caucasian and Japanese subjects: The influence of ethnicity and sex. <i>Pharmacology<\/i> 2013; 91: 331\u2013338.","DOI":"10.1159\/000351704"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, et al. Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017). <i>Circ J<\/i> 2019; 83: 842\u2013945.","DOI":"10.1253\/circj.CJ-66-0158"},{"key":"21","unstructured":"21. European Medicines Agency. Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension. 05 Dec 2011. EMA\/CHMP\/213972\/2010 (accessed January 23, 2026)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bassareo PP, Argiento P, McMahon CJ, Dunne E, Walsh KP, Russo MG, et al. Idiopathic pulmonary arterial hypertension in paediatrics represents still a serious challenge: A case series study. <i>Children (Basel)<\/i> 2023; 10: 518.","DOI":"10.3390\/children10030518"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ishii S, Hatano M, Minatsuki S, Hirose K, Saito A, Yagi H, et al. Comprehensive risk assessment in patients with pulmonary arterial hypertension referred for lung transplantation. <i>Circ J<\/i> 2024; 88: 1610\u20131617.","DOI":"10.1253\/circj.CJ-23-0790"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. <i>Clin Pharmacol Ther<\/i> 2003; 73: 372\u2013382.","DOI":"10.1016\/S0009-9236(03)00005-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Iwasa T, Inuzuka R, Ono H, Sugitani Y, Yamazawa H, Hiraishi C, et al. Safety and efficacy of selexipag for pediatric pulmonary arterial hypertension in Japanese patients: An open-label Phase 2 study. <i>Circ J<\/i> 2025; 89: 1701\u20131708.","DOI":"10.1253\/circj.CJ-24-0429"},{"key":"26","unstructured":"26. Ambrisentan PMDA Report. 2024. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/340278_2190031F1023_1_12 (accessed September 29, 2025)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chen Y, Kirk MD. Incidence of acute respiratory infections in Australia. <i>Epidemiol Infect<\/i> 2014; 142: 1355\u20131361.","DOI":"10.1017\/S0950268813002471"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tamura Y, Kumamaru H, Inami T, Matsubara H, Hirata KI, Tsujino I, et al. Changes in the characteristics and initial treatments of pulmonary hypertension between 2008 and 2020 in Japan. <i>JACC Asia<\/i> 2022; 2: 273\u2013284.","DOI":"10.1016\/j.jacasi.2022.02.011"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/8\/8_CR-26-0077\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:29:12Z","timestamp":1786764552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/8\/8_CR-26-0077\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0077","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"CR-26-0077"}}